litlas
Log inCreate account

Walter M. Stadler

Active 1994–2026

158
Papers
35,665
Citations
95
h-index
155
i10-index

Citations

Citations per year for Walter M. Stadler1956: 1 citations1984: 1 citations1988: 1 citations1991: 1 citations1994: 3 citations1995: 3 citations1996: 15 citations1997: 13 citations1998: 40 citations1999: 42 citations2000: 56 citations2001: 45 citations2002: 74 citations2003: 71 citations2004: 107 citations2005: 177 citations2006: 233 citations2007: 297 citations2008: 312 citations2009: 373 citations2010: 377 citations2011: 417 citations2012: 386 citations2013: 344 citations2014: 280 citations2015: 218 citations2016: 222 citations2017: 233 citations2018: 268 citations2019: 907 citations2020: 1,041 citations2021: 941 citations2022: 717 citations2023: 528 citations2024: 732 citations2025: 364 citations2026: 7 citations1957–1983: no citations, so these years are not shown1985–1987: no citations, so these years are not shown1989–1990: no citations, so these years are not shown1992–1993: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,054 citing papers, 28.7% of this breakdownChina: 1,131 citing papers, 8% of this breakdownUnited Kingdom: 916 citing papers, 6.5% of this breakdownItaly: 817 citing papers, 5.8% of this breakdownFrance: 745 citing papers, 5.3% of this breakdownGermany: 740 citing papers, 5.2% of this breakdownCanada: 608 citing papers, 4.3% of this breakdownSpain: 466 citing papers, 3.3% of this breakdownJapan: 456 citing papers, 3.2% of this breakdownNetherlands: 449 citing papers, 3.2% of this breakdownAustralia: 330 citing papers, 2.3% of this breakdownSwitzerland: 305 citing papers, 2.1% of this breakdown
0%28.7%Other 22.1%

Institutions

Fields

  • Medicine72.5%
  • Biochemistry, Genetics and Molecular Biology20.9%
  • Immunology and Microbiology2.5%
  • Engineering0.9%
  • Mathematics0.7%
  • Computer Science0.4%
  • Other2.1%

Topics

  • Renal cell carcinoma treatment6.9%
  • Cancer Immunotherapy and Biomarkers5.1%
  • Prostate Cancer Treatment and Research5%
  • Bladder and Urothelial Cancer Treatments3.6%
  • Prostate Cancer Diagnosis and Treatment3%
  • Cancer Genomics and Diagnostics2.9%
  • Other73.5%

Coauthors

All papers

Open in search
  1. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

    Authors: Howard I. Scher, Michael J. Morris, Walter M. Stadler, Celestia S. Higano, Ethan Basch, Karim Fizazi, Emmanuel S. Antonarakis, Tomasz M. Beer, Michael A. Carducci, Kim N., Paul G. Corn, Johann S. de Bono, Robert Dreicer, Daniel J. George, Elisabeth I. Heath, Maha Hussain, Wm. Kevin Kelly, Glenn Liu, Christopher J. Logothetis, David M. Nanus, Mark N. Stein, Dana E. Rathkopf, Susan F. Slovin, Charles J. Ryan, Oliver Sartor, Eric J. Small, Matthew Raymond Smith, Cora N. Sternberg, Mary-Ellen Taplin, George Wilding, Peter S. Nelson, Lawrence H. Schwartz, Susan Halabi, Philip W. Kantoff, Andrew J. Armstrong - Journal of Clinical Oncology 2016 cited by 1,603

  2. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

    Authors: David F. McDermott, Mahrukh Huseni, Michael B. Atkins, Robert J. Motzer, Brian I. Rini, Bernard Escudier, Lawrence Fong, Richard W. Joseph, Sumanta K. Pal, James A. Reeves, Mario Sznol, John D. Hainsworth, W. Kimryn Rathmell, Walter M. Stadler, Thomas E. Hutson, Martin Gore, Alain Ravaud, Sergio Bracarda, Cristina Suárez, Riccardo Danielli, Viktor Gruenwald, Toni K. Choueiri, Dorothee Nickles, Suchit Jhunjhunwala, Elisabeth Piault‐Louis, Alpa Thobhani, Jiaheng Qiu, Daniel S. Chen, Priti S. Hegde, Christina Schiff, Gregg Fine, Thomas Powles - Nature Medicine 2018 cited by 1,250

  3. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

    Authors: Brian I. Rini, Thomas Powles, Michael B. Atkins, Bernard Escudier, David F. McDermott, Cristina Suárez, Sergio Bracarda, Walter M. Stadler, Frede Donskov, Jae‐Lyun Lee, Robert D. Hawkins, Alain Ravaud, B. Yа. Alekseev, Michael Staehler, Motohide Uemura, Ugo De Giorgi, Begoña Mellado, Camillo Porta, Bohuslav Melichar, Howard Gurney, Jens Bedke, Toni K. Choueiri, Francis Parnis, Tarik Khaznadar, Alpa Thobhani, Shi Li, Elisabeth Piault‐Louis, Gretchen Frantz, Mahrukh Huseni, Christina Schiff, Marjorie C. Green, Robert J. Motzer - The Lancet 2019 cited by 1,010

  4. Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers

    Authors: Gladell P. Paner, Walter M. Stadler, Donna E. Hansel, Rodolfo Montironi, Daniel W. Lin, Mahul B. Amin - European Urology 2018 cited by 619

  5. Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer

    Authors: Daniel V.T. Catenacci, Melissa R. Junttila, Theodore Karrison, Nathan Bahary, M. Naomi Horiba, Sreenivasa Nattam, Robert Marsh, James A. Wallace, Mark Kozloff, Lakshmi Rajdev, Deirdre Jill Cohen, James L. Wade, Bethany Sleckman, Heinz‐Josef Lenz, Patrick J. Stiff, Pankaj Kumar, Peng Xu, Les Henderson, Naoko Takebe, Ravi Salgia, Xi Wang, Walter M. Stadler, Frédéric J. de Sauvage, Hedy L. Kindler - Journal of Clinical Oncology 2015 cited by 544

  6. Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma

    Authors: Nizar M. Tannir, Neeraj Agarwal, Camillo Porta, Nicola Jane Lawrence, Robert J. Motzer, Bradley A. McGregor, Richard J. Lee, Rohit Jain, Nancy B. Davis, Leonard J. Appleman, Oscar Goodman, Walter M. Stadler, Sunil Gandhi, Daniel M. Geynisman, Roberto Iacovelli, Begoña Mellado, Juan Manuel Sepúlveda-Sánchez, Robert A. Figlin, Thomas Powles, Lalith Akella, Keith Orford, Bernard Escudier - JAMA Oncology 2022 cited by 142

  7. Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma

    Authors: Bernard Escudier, Tim Eisen, Walter M. Stadler, Cezary Szczylik, Stéphane Oudard, Michael Siebels, Sylvie Négrier, Christine Chevreau, E Solska, Apurva A. Desai, Frédéric Rolland, Tomasz Demkow, Thomas E. Hutson, Martin Gore, Sara M. Freeman, Brian Schwartz, Minghua Shan, Ronit Simantov, Ronald M. Bukowski - New England Journal of Medicine 2007 cited by 4,784

  8. Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma

    Authors: Toni K. Choueiri, Thomas Powles, Katriina Peltola, Guillermo de Velasco, Mauricio Burotto, Cristina Suárez, Pooja Ghatalia, Roberto Iacovelli, Elaine T. Lam, Elena Verzoni, Mahmut Gümüş, Walter M. Stadler, Christian Kollmannsberger, Bohuslav Melichar, Balaji Venugopal, Marine Gross‐Goupil, Alexandr Poprach, Maria De Santis, Fabio A. Schutz, Se Hoon Park, Dmitry Nosov, Camillo Porta, Jae‐Lyun Lee, Xavier García del Muro, Elisa Biscaldi, Ray Manneh Kopp, Mototsugu Oya, He Li, Aobo Wang, Rodolfo F. Perini, Donna Vickery, Laurence Albigès, Brian I. Rini - New England Journal of Medicine 2024 cited by 142

  9. Efficacy and Safety of Autologous Dendritic Cell–Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer

    Authors: Nicholas J. Vogelzang, Tomasz M. Beer, Winald R. Gerritsen, Stéphane Oudard, Paweł Wiechno, Bożena Kukiełka-Budny, Vladimír Šámal, Jaroslav Hájek, Susan Feyerabend, Vincent Khoo, Arnulf Stenzl, Tibor Csőszi, Zoran Filipovic, Frederico Gonçalves, А А Прохоров, Eric Cheung, Arif Hussain, Nuno Sousa, Amit Bahl, Syed A. Hussain, Harald Fricke, Pavla Kadlecová, Tomáš Scheiner, Roman Korolkiewicz, Jiřina Bartůňková, Radek Špíšek, VIABLE Investigators, Walter M. Stadler, Arthur Berg, Karl‐Heinz Kurth, Celestia S. Higano, Matti Aapro, Michael Krainer, Stephan Hruby, Johannes Meran, S. Polyakov, Jean‐Pascal Machiels, Thierry Roumeguère, Koen Ackaert, Nicolaas Lumen, Thierry Gil, Velko Minchev, Antoaneta Tomova, Borislav D. Dimitrov, Marchela Koleva, Antonio Juretić, Ana Fröbe, Željko Vojnović, Martin Drabek, L. Jarolím, Tomáš Büchler, Eva Kindlová, Jan Schraml, Milada Zemanová, Prausova Jana, Bohuslav Melichar, Martina Chodacká, Jan Jansa, Gedske Daugaard, Nicolas Delonchamps, Brigitte Duclos, Stéphane Culine, G. Deplanque, Sylvestre Le Moulec, Peter Hammerer, Gerald Rodemer, Manuel Ritter, Axel S. Merseburger, Marc‐Oliver Grimm, Ilija Damjanoski, Manfred Wirth, Martin Burmester, Kurt Miller, Jan Herden, Bastian Keck, Christian Wuelfing, Alexander Winter, Martin Boegemann, Ingo Kausch von Schmeling, Paolo Fornara, E. Jaeger, G. Bodoky, Zsuzsanna Pápai, Géza Böszörményi-Nagy, Paola Vanella, Héctor Soto Parrà, Rodolfo Passalacqua, Francesco Ferraù, Michele Maio, Lucia Fratino, Enrico Cortesi, Gunta Purkalne, Jolita Asadauskienė, Rasa Jančiauskienė, Skaistė Tulytė, Alvydas Česas, Marco B. Polée, Brigitte C.M. Haberkorn, Fons van de Eertwegh, Pieter van den Berg and 83 more - JAMA Oncology 2022 cited by 90

  10. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial

    Authors: Andrew J. Armstrong, Susan Halabi, Tim Eisen, Samuel Broderick, Walter M. Stadler, Robert J. Jones, Jorge A. García, Ulka N. Vaishampayan, Joel Picus, Robert E. Hawkins, John D. Hainsworth, Christian Kollmannsberger, Theodore F. Logan, Igor Puzanov, Lisa Pickering, Christopher W. Ryan, Andrew Protheroe, Christine M. Lusk, Sadie Oberg, Daniel J. George - The Lancet Oncology 2016 cited by 424

  11. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial

    Authors: Naomi B. Haas, Judith Manola, Robert G. Uzzo, Keith T. Flaherty, Christopher G. Wood, Christopher J. Kane, Michael A.S. Jewett, Janice P. Dutcher, Michael B. Atkins, Michael Pins, George Wilding, David Cella, Lynne I. Wagner, Surena F. Matin, Timothy M. Kuzel, Wade J. Sexton, Yu-Ning Wong, Toni K. Choueiri, Роберто Пили, Igor Puzanov, Manish Kohli, Walter M. Stadler, Michael A. Carducci, Robert Coomes, Robert S. DiPaola - The Lancet 2016 cited by 638

  12. LBA88 Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): Randomized open-label phase III LITESPARK-005 study

    Authors: Laurence Albigès, Brian I. Rini, Katriina Peltola, G.A. De Velasco Oria, Mauricio Burotto, C. Suarez Rodriguez, Pooja Ghatalia, Roberto Iacovelli, Elaine T. Lam, Elena Verzoni, M. Gumus, Walter M. Stadler, Christian Kollmannsberger, Bohuslav Melichar, B. Venugopal, Andrew Z. Wang, R. Perini, Donna Vickery, T.B. Powles, Toni K. Choueiri - Annals of Oncology 2023 cited by 53

  13. Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma

    Authors: Toni K. Choueiri, Mayer Fishman, Bernard Escudier, David F. McDermott, Charles G. Drake, Harriet M. Kluger, Walter M. Stadler, José Luis Perez‐Gracia, Douglas G. McNeel, Brendan D. Curti, Michael R. Harrison, Elizabeth R. Plimack, Leonard L. Appleman, Lawrence Fong, Laurence Albigès, Lewis Cohen, Tina C. Young, Scott D. Chasalow, Petra Ross‐Macdonald, Shivani Srivastava, Maria Jure–Kunkel, John F. Kurland, Jason S. Simon, Mario Sznol - Clinical Cancer Research 2016 cited by 292

  14. Phase 1b study of tarlatamab in de novo or treatment-emergent neuroendocrine prostate cancer (NEPC).

    Authors: Rahul Aggarwal, Sylvie Rottey, Alice Bernard‐Tessier, Begoña Mellado-González, Takeo Kosaka, Walter M. Stadler, Shahneen Sandhu, Brian Yu, Crystal Shaw, Chia‐Hsin Ju, Corbin G. Thompson, Ana M. Aparicio - Journal of Clinical Oncology 2024 cited by 28

  15. Molecular Drivers of the Non–T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer

    Authors: Randy F. Sweis, Stefani Spranger, Riyue Bao, Gladell P. Paner, Walter M. Stadler, Gary D. Steinberg, Thomas F. Gajewski - Cancer Immunology Research 2016 cited by 350

  16. Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations

    Authors: Noura J. Choudhury, Alexa Campanile, Tatjana Antic, Kai Lee Yap, Carrie Fitzpatrick, James L. Wade, Theodore Karrison, Walter M. Stadler, Yusuke Nakamura, Peter H. O’Donnell - Journal of Clinical Oncology 2016 cited by 167

  17. Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer

    Authors: Anthony V. Serritella, Daniel Shevrin, Elisabeth I. Heath, James L. Wade, Elia Martinez, Amanda Anderson, Joseph Schonhoft, Yen-Lin Chu, Theodore Karrison, Walter M. Stadler, Russell Z. Szmulewitz - Clinical Cancer Research 2022 cited by 46

  18. Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer

    Authors: Russell Z. Szmulewitz, Cody J. Peer, Abiola Ibraheem, Elia Martinez, Mark Kozloff, Bradley Curtis Carthon, R. Donald Harvey, Paul A. S. Fishkin, Wei Peng Yong, Edmund Chiong, Chadi Nabhan, Theodore Karrison, William D. Figg, Walter M. Stadler, Mark J. Ratain - Journal of Clinical Oncology 2018 cited by 181

  19. Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

    Authors: Bernard Escudier, Tim Eisen, Walter M. Stadler, Cezary Szczylik, Stéphane Oudard, Michael Staehler, Sylvie Négrier, Christine Chevreau, Apurva A. Desai, Frédéric Rolland, Tomasz Demkow, Thomas E. Hutson, Martin Gore, Sibyl Anderson, Gloria Hofilena, Minghua Shan, Carol Peña, Chetan Lathia, Ronald M. Bukowski - Journal of Clinical Oncology 2009 cited by 1,083

  20. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012

    Authors: Maha Hussain, Stephanie Daignault‐Newton, Przemyslaw Twardowski, Costantine Albany, Mark N. Stein, Lakshmi P. Kunju, Javed Siddiqui, Yi-Mi Wu, Dan R. Robinson, Robert J. Lonigro, Xuhong Cao, Scott A. Tomlins, Rohit Mehra, Kathleen A. Cooney, Bruce Montgomery, Emmanuel S. Antonarakis, Daniel H. Shevrin, Paul G. Corn, Young E. Whang, David C. Smith, Megan E.V. Caram, Karen E. Knudsen, Walter M. Stadler, Felix Y. Feng, Arul M. Chinnaiyan - Journal of Clinical Oncology 2017 cited by 210

  21. Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE)

    Authors: Rana R. McKay, Bradley A. McGregor, Wanling Xie, David A. Braun, Xiao X. Wei, Christos E. Kyriakopoulos, Yousef Zakharia, Benjamin L. Maughan, Tracy L. Rose, Walter M. Stadler, David F. McDermott, Lauren C. Harshman, Toni K. Choueiri - Journal of Clinical Oncology 2020 cited by 105

  22. Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401

    Authors: William Kevin Kelly, Susan Halabi, Michael A. Carducci, Daniel J. George, John F. Mahoney, Walter M. Stadler, Michael J. Morris, Philip W. Kantoff, J. Paul Monk, Ellen B. Kaplan, Nicholas J. Vogelzang, Eric J. Small - Journal of Clinical Oncology 2012 cited by 483

  23. Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

    Authors: Brian I. Rini, Susan Halabi, Jonathan E. Rosenberg, Walter M. Stadler, Daniel A. Vaena, San-San Ou, Laura Archer, James N. Atkins, Joel Picus, Piotr Czaykowski, Janice P. Dutcher, Eric J. Small - Journal of Clinical Oncology 2008 cited by 908

  24. Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance)

    Authors: Matthew R. Smith, Susan Halabi, Charles J. Ryan, Arif Hussain, Nicholas J. Vogelzang, Walter M. Stadler, Ralph J. Hauke, J. Paul Monk, Philip J. Saylor, Nirmala Bhoopalam, Fred Saad, Ben L. Sanford, William Kevin Kelly, Michael J. Morris, Eric J. Small - Journal of Clinical Oncology 2014 cited by 250